
Opinion|Videos|October 24, 2024
Impact of Comorbidities on IPF Management
Author(s)Toby Maher, MD, PhD
Key Takeaways
- Comorbidities can obscure IPF symptoms, leading to diagnostic delays or misdiagnoses, complicating the clinical presentation.
- Comprehensive evaluation is crucial to tailor treatment plans addressing both IPF and comorbidities effectively.
Toby Maher, MD, PhD, discusses how comorbidities complicate the diagnosis and management of idiopathic pulmonary fibrosis (IPF) and influence treatment decisions, highlighting the need for a comprehensive approach in patient care.
Advertisement
Episodes in this series

Video content above is prompted by the following:
How do comorbidities affect diagnosis and management of IPF? In what ways do comorbidities affect treatment decisions?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
In CLL, Fixed-Duration Venetoclax Combos Are Equal to Continuous Ibrutinib in Head-to-Head Comparison
2
ASH 2025 Offers Data That Could Make Novel Therapies More Accessible
3
Fixed-Duration Epcoritamab Plus Chemotherapy Yields Response, Remissions in DLBCL
4
Once-Monthly Maridebart Cafraglutide Shows Up to 16% Weight Loss
5















































